This is a report of progress made towards achieving international targets for tuberculosis control by 2015
This paper is based on a presentation given in the Philippines on the right to health. Several topics were tackled there, from drug prices and price control, to drug availability, patent for new medicines, health insurance, among others. The focus was on the philosophy of 'health as a right' juxtaposed with 'health as personal responsibility'. The paper concludes that rather than favouring one group of pharma companies and demonising another, public policy should focus on expanding the people’s options in choosing the right mixture of medicines and healthcare that are appropriate for them given their existing resources and health needs
The unique position of stakeholders participating in the Medicines Transparency Alliance Zambia, means that the group are able to initiate discussions at many levels from grassroots to parliament. This is of great value in highlighting critical issues about the lack of access to essential medicines experienced by many citizens in Zambia and makes progress towards finding some solutions
The local manufacturing of pharmaceuticals is a hotly contested issue in many countries. It runs to the heart of key concerns such as quality, availability, and price of medicines. Some of the arguments of the local manufacturers are set out in this article by one of the co-chairs of the Medicines Transparency Alliance Uganda Council and Chairman of the Uganda Pharmaceutical Manufacturer's Association (UPMA)
This issue has articles about medicine prices in Vietnam, Thailand and South Africa, generic medicines in Malaysia and Australia, anti-retroviral therapy in South Africa, and legislation and regulation in the retail pharmacy sector in low-income countries.
Southern Med Review : Vol 2, Issue 2
This paper argues that, between North and South, there are more common health interests in pharmaceutical policies, within broader global public policies, than are currently articulated
"This report presents the findings of the first phase of the [World Health Organization's] national Good Governance for Medicines programme in the Syrian Arab Republic. The assessment aims to obtain a picture of the level of transparency and potential vulnerability to corruption in the public pharmaceutical sector using WHO’s assessment instrument. In the Syrian Arab Republic, the assessment looked at eight functions: medicines registration, licensing of pharmaceutical establishments, inspection of pharmaceutical establishments, promotion, selection, clinical trials, procurement and distribution"
This paper analyses the philosophical, legal and political basis for declaring price control of any commodity in general, and medicine products in particular. It also discusses the evolution of policies and political events that coincide with the declaration and implementation of drug price control in the Philippines, and the policy’s impact on the various players and consumers in the country. The paper concludes that more competition, not more regulations like price control, will bring down medicine prices both in the short-term and long-term
This blog sets out the need for a transparent medicine pricing mechanism in the Philippines backed up by the development of a responsive, competitive pharmaceutical sector capable of undertaking science and technology activities
This is a rapid review of how 13 countries have addressed the issue of now to make new and expensive treatments available under a statutory health system, given limited resources
This manual is to help governments, civil society groups and others concerned about the prices of medicines to collect and analyse: medicine prices (patient prices and government procurement prices) across sectors and regions in a country; medicine availability; treatment affordability; and all price components in the supply chain from manufacturer to patient (taxes, mark-ups etc.). It is accompanied by a CD-ROM which contains a more extensive collection resources and tools, such as sample training materials, frequently asked questions, and a report template for use in developing national survey reports
At a time when over 50 medicines pricing surveys had been completed around the world using the HAI/WHO methodology, the lead article to this edition of the medicines pricing survey bulletin considers the need for guidelines to assist in the creation of policy changes that will help to reduce the price of essential medicines
These draft guidelines consider human rights and the right to the highest attainable standard of health; how to manage their implementation; public policy influence; advocacy and lobbying; research and development for neglected diseases; patents and licensing; quality and technology transfer; pricing, discounting and donations; ethical promotion and marketing; clinical trials; public private partnership; corruption; associations of pharmaceutical companies; and monitoring and accountability
Distribution is an important activity in the management of pharmaceuticals involving a number of steps between arrival in the port of entry to the point of supply to health establishment, each of which can present various opportunities for lack of transparency and invites corruption. Published standard operating procedures which specify the roles and responsibilities of all staff involved in each of these steps are important tools that promote transparency and accountability
"Poor drug access continues to be one of the main global health problems. Global inequalities in access to pharmaceuticals are caused by a number of variables including poverty, high drug prices, poor health infrastructure, and fraud and corruption - the latter being the subject of this article"
The focus of this edition of HAI and WHO's bulletin for medicines prices surveys is a meeting of the regional committee of the WHO's Eastern Mediterranean region (EMRO) at which the results of 11 medicines pricing surveys carried out in the region were compared and discussed and it was decided to share information regionally
This is the report of the Department of Technical Cooperation for Essential Drugs and Traditional Medicine, WHO meeting which provided a forum for sharing experiences from the ongoing regional and global pooled procurement programmes and explored priority areas for inter-regional collaboration. The meeting brought together experts from various regional and global initiatives, representatives of sub-regional economic groups and development partners interested in pooled procurement and was organised to include plenary presentations on lessons learnt, i.e. strategies, achievements and constraints, and group work and discussions on the key principles of effective pooled procurement
These are the slides for a presentation about the WHO's Good Governance in Medicines Programme which aims to address the problems of corruption and unethical practices
This paper focuses on the values approach for promoting ethical practices in the governance and management of pharmaceuticals within ministries of health. It recognises the need to coordinate and integrate such endeavours with existing legislative efforts to establish a legal framework and ethical infrastructure that adequately address the problem of corruption within the context of each country. The paper is a working draft for field testing and revision
"This paper provides a brief overview of what the international human rights instruments mention about access to essential medicines, and proposes five assessment questions and practical recommendations for governments. These recommendations cover the selection of essential medicines, participation in programme development, mechanisms for transparency and accountability, equitable access by vulnerable groups, and redress mechanisms"
Source e-bulletin on Disability and Inclusion